• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

RSNA23: iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI

by RSNA23 Announcements 11/29/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI

What You Should Know:

– iCAD, Inc. (NASDAQ: ICAD), a provider of medical technology and innovative cancer-detection solutions, announced that its ProFound Breast Health Suite will be integrated into GE HealthCare’s new MyBreastAI Suite offering.

– This integration coincides with GE HealthCare’s and iCAD’s presence at the Radiological Society of North America (RSNA) annual meeting in Chicago as it unveils new research evaluating its ProFound AI in breast cancer risk detection and heart disease.

Advancing Breast Cancer Detection with AI

Breast cancer is the most commonly diagnosed cancer worldwide, and iCAD’s AI solutions are designed to address critical issues in breast imaging, including access, burnout, variability, equity, and cost. GE HealthCare’s MyBreastAI Suite, featuring iCAD’s three key AI-enabled solutions from ProFound Breast Health Suite, aims to streamline workflow and help clinicians in accelerating breast cancer detection and delivering more personalized and effective breast care.

iCAD’s AI-Powered Solutions

The MyBreastAI Suite will initially offer three AI applications from iCAD:

– ProFound Detection for Digital Breast Tomosynthesis (DBT): This deep-learning AI workflow solution rapidly evaluates 3D mammograms to detect malignant soft tissue densities and calcifications with unmatched accuracy. ProFound Detection provides Lesion Scores and Case Scores, aiding in clinical decision-making, workload prioritization, and potentially reducing burnout.

– SecondLook for 2D Mammography: Utilizes AI to identify potential cancers in 2D mammography, marking suspicious areas promptly and clearly.

– PowerLook Density Assessment: Automates breast density evaluation, providing an objective, reproducible measure that is crucial for personalized screening recommendations.

Clinical Benefits of iCAD’s AI Solutions

Clinical studies have demonstrated that the use of iCAD’s ProFound AI solutions can significantly improve reading sensitivity and specificity, as well as reduce reading times, thus enhancing clinical decision support and workflow efficiency for radiologists. Specifically, ProFound AI offers clinically proven time-saving benefits to radiologists, including a reduction of reading time by 52.7%, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8% and reduced unnecessary patient recall rates by 7.2%.

Availability and Collaboration

MyBreastAI Suite, featuring key iCAD AI-enhanced solutions, will be available first in the United States and distributed, installed, and supported by GE HealthCare as part of their Senographe Pristina mammography portfolio.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Breast Cancer

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |